Evidence map›Paper›PMID 37537380›Full record

ArticleHeart and vessels2024

Prognostic utility of serum NT-proBNP (fragments 1-76aa and 13-71aa) and galectin-3 in predicting death and re-hospitalisation due to cardiovascular events in patients with heart failure.

Xi Zhang, Yunxia Wan, Nuwan Karunathilaka, Wandy Chan, Karam Kostner, Gunter Hartel, Andrew J S Coats, John J Atherton, Chamindie Punyadeera

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heart and vessels, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Neurohumoral Activation in Heart Failure.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Xi Zhang *Saliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery, Griffith University, 46, Don Young Rd, Nathan, QLD, 4111, Australia.
Yunxia Wan *Saliva and Liquid Biopsy Translational Laboratory, The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia.
Nuwan KarunathilakaSaliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery, Griffith University, 46, Don Young Rd, Nathan, QLD, 4111, Australia.
Wandy ChanThe Prince Charles Hospital, Brisbane, QLD, Australia.
Karam KostnerDepartment of Cardiology, Mater Adult Hospital, Brisbane, QLD, Australia.
Gunter HartelStatistics Unit, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Andrew J S CoatsFaculty of Medicine, Monash University, Melbourne, VIC, Australia.
John J AthertonCardiology Department, Faculty of Medicine, Royal Brisbane and Women's Hospital and University of Queensland, Brisbane, QLD, Australia.
Chamindie PunyadeeraSaliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery, Griffith University, 46, Don Young Rd, Nathan, QLD, 4111, Australia. c.punyadeera@griffith.edu.au.ORCID http://orcid.org/0000-0001-9039-8259
Griffith University · AUThe University of Queensland · AUMater Adult Hospital · AUQIMR Berghofer Medical Research Institute · AUTranslational Research Institute · AUUniversity of Warwick · GB

Funding

Cancer Australia APP1145657National Health and Medical Research Council 2002576National Health and Medical Research Council 2012560
6 · The paper itself

Abstract

Patients with heart failure (HF) are at a higher risk of rehospitalisation. In this study, we investigated the prognostic utility of galectin-3 (Gal-3) and NT-proBNP fragments (1-76aa and 13-71aa) as biomarkers to predict outcomes for patients with HF. We collected blood samples from patients with HF (n = 101). Gal-3 and NT-proBNP fragments (1-76aa and 13-71aa) concentrations were measured by immunoassay. Survival analysis and Cox proportional regression models were used to determine the prognostic utility of Gal-3 and NT-proBNP fragments. In patients with increased baseline levels of NT-proBNP

Indexed as

Galectin 3Heart FailureBiomarkersHospitalizationHumansNatriuretic Peptide, BrainPeptide FragmentsPrognosisBiomarkersGalectin 3Natriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Gal-3Heart failureNT-proBNPPrognosis

Identifiers

PMID37537380
PMCPMC10764512
OpenAlexW4385555556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.